OpenSecrets reports that 17 drug companies in TrumpRx boosted lobbying by 23% to over $130M in 2025, outpacing the broader ...
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity ...
BEIJING -- A Chinese research team has announced a key breakthrough in the space-based gravitational wave detection program ...
AiTradeBtc announces expanded access to AI-based trading automation tools designed for continuous market monitoring and ...
NKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory benefit in ARDS — ...
Endocrine therapy is one of the top predictors of sexual dysfunction in women cancer survivors, according to a study shown at ...
Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced ...
As pharmaceutical companies push changes to the 340B drug pricing program, safety-net hospitals serving Black and low-income ...
Publication of a peer-reviewed study from Alterity Therapeutic’s bioMUSE study shows an advanced MRI imaging method detects ...
The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene ...
While many policy experts agree Social Security faces long-term financing challenges, they often disagree on a core part of ...
Content by Methodist Health System. As more adults live longer, the way we care for older patients matters more than ever.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results